Cooley Law Firm Recognized in China Business Law Journal’s Deals of the Year Awards

Beijing, Shanghai and Hong Kong – March 6, 2026 – Cooley has been honored for its work on several significant deals in the Chinese market, receiving recognition in the 2025 China Business Law Journal (CBLJ) “Deals of the Year” awards. The awards, announced on March 6, 2026, acknowledge landmark transactions completed between November 1, 2024, and October 31, 2025.

Award-Winning Deals

Cooley secured recognitions in five categories:

• Intellectual Property (Life Sciences Corporate Partnering and Licensing): 3SBio’s exclusive licensing of SSGJ-707 to Pfizer.
• Intellectual Property (Life Sciences Corporate Partnering and Licensing): Hengrui Pharma’s US$12.5 billion collaboration, option and license agreement with GSK.
• Equity Capital Markets: DualityBio’s HK$1.64 billion Hong Kong initial public offering.
• Private Equity and Venture Capital: SJ Semiconductor’s US$700 million financing round.
• Private Equity and Venture Capital: Robotics startup Genesis AI on its US$105 million seed-round financing.

About the China Business Law Journal Deals of the Year Awards

The China Business Law Journal “Deals of the Year” awards recognize exceptional legal work and innovative transactions that set precedents in the Chinese market [1]. The evaluation process considers factors such as deal size, industry impact, structural innovation, and the long-term value created for clients and society [3]. The judging panel adheres to non-commercial principles, with no fees or obligations associated with submissions or judging [3].

Cooley’s Presence in Greater China

Cooley has maintained a strong presence in Greater China for nearly four decades, with offices in Shanghai, Beijing, and Hong Kong. The firm provides legal services to companies and investors in the region, specializing in technology, healthcare, and life sciences [1]. Cooley advises clients throughout their corporate lifecycle, from startup to maturity, and supports both local growth and global expansion [1].

The firm’s expertise includes fund formation, financing, mergers and acquisitions, joint ventures, capital markets, licensing, and cross-border transactions.